The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer.

Find People
Find Research
Overview
Tutorials
FAQs
Edit My PROFILE
Login to PROFILES

History

Long-term Clinical Out

Milgrom, Sarah

Mucosal immunity and t

Increased mortality at

The Mitogen-Activated

See All (8) pages

Contact Us
If you have any questions or feedback please contact us.

The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer.

Beadnell TC, Mishall KM, Zhou Q, Riffert SM, Wuensch KE, Kessler BE, Corpuz ML, Jing X, Kim J, Wang G, Tan AC, Schweppe RE. The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer. Mol Cancer Ther. 2016 08; 15(8):1952-63.

View in: PubMed

subject areas

Animals
Antineoplastic Agents
Cell Death
Cell Line, Tumor
Dasatinib
Disease Models, Animal
Drug Resistance, Neoplasm
Female
Genes, ras
Humans
MAP Kinase Signaling System
Mice
Mutation
Protein Kinase Inhibitors
Proto-Oncogene Proteins B-raf
src-Family Kinases
Thyroid Neoplasms
Xenograft Model Antitumor Assays

authors with profiles

Rebecca E Schweppe

Contact Us
CCTSI
About CCTSI
CCTSI Affiliated Institutions
National CTSA Consortium